Tech Company M&A Transactions
Acerta Pharma Acquisition
Acerta Pharma was purchased by AstraZeneca. The transaction became public on 12/17/2015. AstraZeneca said the transaction price was $4 billion.
Transaction Overview
Company Name
Acquired By
Announced On
12/17/2015
Transaction Type
M&A
Amount
$4,000,000,000
M&A Terms
AstraZeneca is to buy 55 percent of privately held biotech firm Acerta Pharma for $4 billion to give it access to a new kind of blood cancer drug, boosting its long-term growth at the cost of a near-term hit to earnings.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
2200 Bridge Pkwy. 101
Redwood City, CA 94065
USA
Redwood City, CA 94065
USA
Phone
Website
Email Address
Overview
Acerta Pharma B.V. offers drug discovery and development services for oncology and autoimmune diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Flavia Borellini
Chief Scientific Officer
Andrew Mortlock
Executive Vice President
Tjeerd Barf
Executive Vice President
Allard Kaptein
VP - Client Services
Ahmed Hamdy
VP - Client Services
Naomi Hunder
VP - Client Services
Greg Slatter
VP - Manufacturing
Peter Carbonaro
VP - Operations
Michele Fernandes
VP - Operations
Emily Roberts-Thomson
VP - Regulatory Affairs
Raquel Izumi
Browse more venture capital transactions:
Prev: 12/17/2015: Kount venture capital transaction
Next: 12/17/2015: DealCloud venture capital transaction
Share this article
About Our Venture Capital Transactions Database
Our team works diligently to record every notable VC transaction. VC investment data records reported here are derived from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs